Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant TACE after resection for HCC
NCT00820053Phase 2Completed
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Jan 2009
- Primary completion
- Dec 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epirubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoint: Overall Survival at 3 years. Started Jan 2009; status: completed.
02
Drugs
epirubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00820053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00820053.